Lombard Odier Asset Management Switzerland SA Has $12.27 Million Stock Holdings in Amgen Inc. $AMGN

Lombard Odier Asset Management Switzerland SA raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 21.4% during the 4th quarter, HoldingsChannel reports. The firm owned 37,472 shares of the medical research company’s stock after purchasing an additional 6,611 shares during the quarter. Lombard Odier Asset Management Switzerland SA’s holdings in Amgen were worth $12,265,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Vanguard Group Inc. grew its position in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp grew its position in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors grew its position in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Capital International Investors grew its position in shares of Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after purchasing an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.8%

AMGN stock opened at $347.84 on Wednesday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The company has a market cap of $187.73 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 3.52 and a beta of 0.42. The business’s 50-day simple moving average is $341.02 and its 200 day simple moving average is $345.89. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the company earned $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AMGN shares. Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 price target on shares of Amgen in a research report on Thursday, March 5th. Rothschild & Co Redburn raised their price objective on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Friday. Royal Bank Of Canada raised their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Finally, Argus lowered their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $354.42.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.